Ligand Pharmaceuticals (LGND) said Tuesday it continues to expect 2025 core adjusted earnings of $7.40 to $7.65 per diluted share.
Analysts polled by FactSet expect $7.62.
The company also reiterated its full-year core revenue outlook range of $225 million to $235 million.
For 2026, Ligand projects core adjusted EPS at $8 to $9 on revenue of $245 million to $285 million. Analysts polled by FactSet expect $7.97 and $259.2 million, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments